1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove

9% Disease Free After Phase II Study

 
• By Andrew McConaghie

GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.

Hepatitis B virus
Hepatitis B has so far proven very difficult to suppress - but GSK is hoping to achieve a functional cure for more patients in its Phase III study • Source: Shutterstock

Recent weeks have seen a flurry of Phase III trial readouts from GSK, ranging from a definite ‘win’ (for its RSV vaccine) to a clear failure (with myeloma therapy Blenrep) in the company’s efforts to bring a new generation of blockbusters to market. The firm has now added to this with Phase II results showing a small number of patients have achieved a functional cure when treated with its chronic hepatitis B (CHB) candidate bepirovirsen. (Also see "GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market" - Scrip, 7 November, 2022.) 

The data might not be a clear win just yet, but do set up GSK to move in to Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from R&D

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.